Alzheimer's disease & dementia

Phase III aducanumab trials for Alzheimer's disease stopped early

Pharmaceutical companies Biogen and Eisai today (Thursday 21 March) announced they are to discontinue two phase III trials of the Alzheimer's drug aducanumab. The ENGAGE and EMERGE trials were designed to evaluate the efficacy ...

Medical research

Searching for side effects

Extracting relevant information from the scientific literature about side effects and adverse drug reactions to pharmaceutical products is an important part of data mining in this area. Writing in the International Journal ...

page 31 from 40